Literature DB >> 31791887

Prevalence, Outcomes and Cost Implications of Patients Undergoing Same Day Discharge After Elective Percutaneous Coronary Intervention in Australia.

Stephanie Liew1, Diem Dinh2, Danny Liew2, Angela Brennan2, Stephen Duffy3, Christopher Reid4, Jeffrey Lefkovits5, Dion Stub6.   

Abstract

BACKGROUND: Despite international growth in the use of same day percutaneous coronary intervention (PCI), its widespread use remains limited. This study sought to determine the prevalence, clinical outcomes and cost implications of same day discharge (SDD) amongst Australian patients undergoing elective PCI.
METHODS: This is a retrospective, observational cohort study of patients who underwent elective PCI in Victoria between January 2014 and December 2017. Data from this study was obtained from the Victorian Cardiac Outcomes Registry (VCOR). The primary outcome measured was the incidence of 30-day major adverse cardiac events (MACE) and secondary outcomes included in hospital complications and 30-day readmissions, between SDD patients and those observed as inpatients overnight (ON). Propensity score matching for key clinical factors were used to compare both groups.
RESULTS: We studied 18,101 patients, with a mean age of 68±11years and 13,935 (77%) were male. The rate of SDD was 586 (3.2%) and 17,515 (96.8%) patients stayed in hospital overnight. Radial access was performed in 393 (67.1%) and 7,967 (45.5%) among SDD and ON patients respectively (p<0.001). At 30 days, unplanned cardiac re-hospitalisation occurred in 9.6% (n=56) amongst SDD and 11.6%, (n=2,033) amongst ON patients (p=0.173). Propensity matching highlighted SDD to be non-inferior to overnight, with no significant difference in 30-day MACE (0.5%, 95% CI: 0.34, 1.35) but SDD was associated with reduced average length of stay by 2.06 days (95% CI: 1.94, 2.19). We observed substantial hospital variation for SDD from 0% to 16.6% of elective PCI procedures.
CONCLUSIONS: Same day discharge after elective PCI is performed infrequently in Victoria. Despite this, SDD appears to be safe and feasible. Given significant benefits in cost and bed utilisation, a more consistent use of SDD could markedly improve the value of PCI care in Australia.
Copyright © 2019 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Coronary intervention; Length of stay; Same Day PCI

Mesh:

Year:  2019        PMID: 31791887     DOI: 10.1016/j.hlc.2019.09.005

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  5 in total

Review 1.  Safety and feasibility of same-day discharge following catheter ablation of atrial fibrillation: what is known and what needs to be explored?

Authors:  Sebastian König; Sergio Richter; Andreas Bollmann; Gerhard Hindricks
Journal:  Herz       Date:  2022-03-07       Impact factor: 1.443

2.  Safety, Feasibility and Economic Analysis of Same Day Discharge Following Elective Percutaneous Coronary Intervention.

Authors:  Kais Hyasat; Giuseppe Femia; Karam Alzuhairi; Andrew Ha; Joseph Kamand; Edmund Hasche; Rohan Rajaratnam; Sidney Lo; Hamid Almafragy; Kevin Liou; Joseph Chiha; Kaleab Asrress
Journal:  Clin Med Insights Cardiol       Date:  2022-08-23

3.  Early discharge of patients (within 24 h) after percutaneous coronary intervention is feasible and safe in Indian setup.

Authors:  Refai Showkathali; Radhapriya Yalamanchi; Abraham Oomman
Journal:  Indian Heart J       Date:  2020-04-08

4.  Same-day discharge after elective percutaneous transluminal coronary angioplasty: An instruction manual and call for increased uptake in a burdened National Health Service.

Authors:  Miguel Borges Santos
Journal:  Rev Port Cardiol (Engl Ed)       Date:  2020-08-05

5.  Estimating the economic impacts of percutaneous coronary intervention in Australia: a registry-based cost burden study.

Authors:  Peter Lee; Angela L Brennan; Dion Stub; Diem T Dinh; Jeffrey Lefkovits; Christopher M Reid; Ella Zomer; Danny Liew
Journal:  BMJ Open       Date:  2021-12-07       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.